Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2019067667) COMPOSITIONS PHARMACEUTIQUES À PERMÉATION AMÉLIORÉE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS:

What is claimed is:

1. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

an adrenergic receptor interacter.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further includes a permeation enhancer.

3. The pharmaceutical composition according to claim 1, wherein the adrenergic receptor interacter includes a terpenoid, a terpene, or a sesquiterpene.

4. The pharmaceutical composition according to claim 2, wherein the permeation enhancer includes farnesol or Labrasol.

5. The pharmaceutical composition according to claim 2, wherein the permeation enhancer includes linoleic acid.

6. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a film further comprising a polymeric matrix, the pharmaceutically active component being contained in the polymeric matrix.

7. The pharmaceutical composition according to claim 1, wherein the adrenergic receptor interacter includes a phenylpropanoid.

8. The pharmaceutical composition according to claim 7, wherein the phenylpropanoid is eugenol or eugenol acetate.

9. The pharmaceutical composition according to claim 7, wherein the phenylpropanoid is a cinnamic acid, cinnamic acid ester, cinnamic aldehyde or hydrocinnamic acid.

10. The pharmaceutical composition according to claim 7, wherein the phenylpropanoid is chavicol.

11. The pharmaceutical composition according to claim 7, wherein the phenylpropanoid is safrole.

12. The pharmaceutical composition according to claim 1, wherein the adrenergic receptor interacter is a phytoextract.

13. The pharmaceutical composition according to claim 12, wherein the phytoextract further includes an essential oil extract of a clove plant.

14. The pharmaceutical composition according to claim 12, wherein the phytoextract further includes an essential oil extract of a leaf of a clove plant.

15. The pharmaceutical composition according to claim 12, wherein the phytoextract further includes an essential oil extract of a flower bud of a clove plant.

16. The pharmaceutical composition according to claim 12, wherein the phytoextract further includes an essential oil extract of a stem of a clove plant.

17. The pharmaceutical composition according to claim 12, wherein the phytoextract is synthetic or biosynthetic.

18. The pharmaceutical composition according to claim 12, wherein the phytoextract further includes 40-95% eugenol.

19. The pharmaceutical composition according to claim 1, wherein the pharmaceutically active component is epinephrine, diazepam, or alprazolam.

20. The pharmaceutical composition according to claim 1, wherein the polymer matrix includes a polymer.

21. The pharmaceutical composition according to claim 20, wherein the polymer includes a water soluble polymer.

22. The pharmaceutical composition according to claim 20, wherein the polymer includes a cellulosic polymer selected from the group of: hydroxypropylmethyl cellulose, hydroxy ethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and carboxymethyl cellulose.

23. The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is a chewable or gelatin based dosage form, spray, gum, gel, cream, tablet, liquid or film.

24. The pharmaceutical composition according to claim 20, wherein the polymeric matrix comprises a polyethylene oxide, cellulosic polymer, polyethylene oxide and polyvinyl pyrrolidone, polyethylene oxide and a polysaccharide, polyethylene oxide, hydroxypropyl methylcellulose and a polysaccharide, or polyethylene oxide, hydroxypropyl methylcellulose, polysaccharide and polyvinylpyrrolidone.

25. The pharmaceutical composition according to claim 20, wherein the polymeric matrix comprises at least one polymer selected from the group of: pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, ethylene oxide, propylene oxide co-polymers, collagen, albumin, poly-amino acids, polyphosphazenes, polysaccharides, chitin, chitosan, and derivatives thereof.

26. The pharmaceutical composition according to claim 1, further comprising a stabilizer.

27. The pharmaceutical composition according to claim 1, wherein the polymeric matrix comprises a dendritic polymer or a hyperbranched polymer.

28. A method of making a pharmaceutical composition comprising:

combining an adrenergic receptor interacter with a pharmaceutically active component and

forming a pharmaceutical composition including the adrenergic receptor interacter and the pharmaceutically active component.

29. A device comprising

a housing that holds an amount of a pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix and

an adrenergic receptor interacter; and

an opening that dispenses a predetermined amount of the pharmaceutical composition.

30. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

an aporphine alkaloid interacter.

31. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

a vasodilator interacter.

32. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

an interacter that creates increased blood flow or enables a flushing of the tissue to modify transmucosal uptake of the pharmaceutically active component.

33. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

an interacter that has a positive or negative heat of solution which are used as aids to modify transmucosal uptake.

34. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and

an interacter, the composition contained in a multilayer film having at least one side where the edges are coterminous.

35. A method of treating a medical condition comprising

administering an effective amount of pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component in the polymeric matrix; and an adrenergic receptor interacter.

36. The method of claim 35, wherein the pharmaceutically active component is epinephrine,diazepam, or alprazolam.

37. The method of claim 35, wherein the medical condition includes a symptom of epilepsy.

38. The method of claim 35, wherein the composition includes diazepam administered during an interictal state.

39. The method of claim 35, wherein the composition includes diazepam =administered during an ictal state.

40. The method of claim 35, wherein the composition includes diazepam administered during a periictal state.

41. The method of claim 35, wherein the medical condition includes anxiety, drug withdrawal, parasomnia, alcohol withdrawal, muscle spasms, or seizure disorder.

42. The method of claim 35, wherein the medical condition includes treatment as a sedative.

43. The method of claim 35, wherein the medical condition includes sedation for a medical procedure.